Completed PHASE2 INTERVENTIONAL 1-arm NCT02562573

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Sponsor: Liminal BioSciences Ltd.

Conditions Metabolic Syndrome Type 2 Diabetes

Interventions PBI4050

Updated 6 times since 2017 Last updated: Apr 10, 2017 Started: May 31, 2015 Primary completion: Nov 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metabolic Syndrome and Type 2 Diabetes and is currently completed. Liminal BioSciences Ltd. leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Liminal BioSciences Ltd.

Data source: Liminal BioSciences Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada